Loading...
IL22BP Mediates the Anti-Tumor Effects of Lymphotoxin Against Colorectal Tumors in Mice and Humans.
Kempski, Jan Giannou, Anastasios D Riecken, Kristoffer Zhao, Lilan Steglich, Babett Lücke, Jöran Garcia-Perez, Laura Karstens, Karl-Frederick Wöstemeier, Anna Nawrocki, Mikolaj
Kempski, Jan
Giannou, Anastasios D
Riecken, Kristoffer
Zhao, Lilan
Steglich, Babett
Lücke, Jöran
Garcia-Perez, Laura
Karstens, Karl-Frederick
Wöstemeier, Anna
Nawrocki, Mikolaj
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2020-06-18
Submitted date
Files
Loading...
Pre-Proof
Adobe PDF, 16.71 MB
Other Titles
Abstract
We obtained tumor and non-tumor tissues from patients with colorectal cancer (CRC) and measured levels of cytokines by quantitative PCR, flow cytometry, and immunohistochemistry. We measured levels of Il22bp mRNA in colon tissues from wild-type, Tnf-/-, Lta-/-, and Ltb-/- mice. Mice were given azoxymethane and dextran sodium sulfate, to induce colitis and associated cancer, or intra-caecal injections of MC38 tumor cells. Some mice were given inhibitors of lymphotoxin beta receptor (LTBR). Intestine tissues were analyzed by single-cell sequencing to identify cell sources of lymphotoxin. We performed immunohistochemistry analysis of colon tissue microarrays from patients with CRC (1475 tissue cores, contained tumor and non-tumor tissues) and correlated levels of IL22BP with patient survival times.
Citation
Gastroenterology. 2020;S0016-5085(20)34833-2. doi:10.1053/j.gastro.2020.06.033.
Publisher
Journal
PubMed ID
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
en
Description
Series/Report no.
ISSN
EISSN
1528-0012